Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYTK NASDAQ:KRYS NASDAQ:KYMR NASDAQ:QURE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$84.87$77.25$32.89▼$88.31$10.56B0.422.47 million shs1.77 million shsKRYSKrystal Biotech$365.81$325.15$130.50▼$382.54$10.78B0.5352,867 shs363,546 shsKYMRKymera Therapeutics$119.35$90.61$36.65▼$130.05$9.82B1.951.26 million shs665,608 shsQUREuniQure$42.63$33.03$8.73▼$71.50$2.69B0.92.96 million shs1.14 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics0.00%-1.87%+20.98%+27.20%+129.32%KRYSKrystal Biotech0.00%-2.47%+15.05%+36.80%+146.89%KYMRKymera Therapeutics0.00%+5.14%+38.44%+34.81%+168.32%QUREuniQure0.00%+1.96%+54.62%+137.89%+196.04%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$84.87$77.25$32.89▼$88.31$10.56B0.422.47 million shs1.77 million shsKRYSKrystal Biotech$365.81$325.15$130.50▼$382.54$10.78B0.5352,867 shs363,546 shsKYMRKymera Therapeutics$119.35$90.61$36.65▼$130.05$9.82B1.951.26 million shs665,608 shsQUREuniQure$42.63$33.03$8.73▼$71.50$2.69B0.92.96 million shs1.14 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics0.00%-1.87%+20.98%+27.20%+129.32%KRYSKrystal Biotech0.00%-2.47%+15.05%+36.80%+146.89%KYMRKymera Therapeutics0.00%+5.14%+38.44%+34.81%+168.32%QUREuniQure0.00%+1.96%+54.62%+137.89%+196.04%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTKCytokinetics 2.91Moderate Buy$99.9017.71% UpsideKRYSKrystal Biotech 2.83Moderate Buy$340.56-6.90% DownsideKYMRKymera Therapeutics 2.91Moderate Buy$121.411.73% UpsideQUREuniQure 2.65Moderate Buy$64.1750.52% UpsideCurrent Analyst Ratings BreakdownLatest QURE, KRYS, CYTK, and KYMR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/13/2026KYMRKymera Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform7/7/2026CYTKCytokinetics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$119.00 ➝ $117.007/1/2026KRYSKrystal Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)6/30/2026KYMRKymera Therapeutics Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$110.00 ➝ $125.006/29/2026KYMRKymera Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$117.00 ➝ $155.006/29/2026KYMRKymera Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$116.00 ➝ $136.006/29/2026CYTKCytokinetics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$69.00 ➝ $115.006/29/2026QUREuniQure HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $80.006/26/2026QUREuniQure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/26/2026KYMRKymera Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$106.00 ➝ $129.006/25/2026QUREuniQure MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$35.00 ➝ $68.00(Data available from 7/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTKCytokinetics$105.82M99.80N/AN/A($5.39) per share-15.75KRYSKrystal Biotech$389.13M27.71$7.29 per share50.18$42.06 per share8.70KYMRKymera Therapeutics$51.48M190.72N/AN/A$19.42 per share6.15QUREuniQure$16.10M167.00N/AN/A$3.19 per share13.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTKCytokinetics-$784.96M-$6.84N/AN/AN/A-784.02%N/A-52.86%8/6/2026 (Estimated)KRYSKrystal Biotech$204.83M$7.4848.9134.81N/A53.92%19.25%17.62%8/3/2026 (Estimated)KYMRKymera Therapeutics-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%8/10/2026 (Estimated)QUREuniQure-$198.97M-$3.48N/AN/AN/A-1,154.42%-145.81%-27.15%8/4/2026 (Estimated)Latest QURE, KRYS, CYTK, and KYMR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2026Q2 2026KYMRKymera Therapeutics-$0.7266N/AN/AN/A$31.17 millionN/A8/6/2026Q2 2026CYTKCytokinetics-$1.64N/AN/AN/A$17.09 millionN/A8/4/2026Q2 2026QUREuniQure-$0.8261N/AN/AN/A$5.45 millionN/A8/3/2026Q2 2026KRYSKrystal Biotech$1.80N/AN/AN/A$123.63 millionN/A5/5/2026Q1 2026CYTKCytokinetics-$1.67-$1.67N/A-$1.67$8.52 million$19.36 million5/5/2026Q1 2026QUREuniQure-$0.88-$0.85+$0.03-$0.85$5.21 million$3.56 million5/4/2026Q1 2026KRYSKrystal Biotech$1.45$1.83+$0.38$1.83$112.11 million$116.36 million4/30/2026Q1 2026KYMRKymera Therapeutics-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCYTKCytokineticsN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTKCytokineticsN/A4.214.21KRYSKrystal BiotechN/A9.469.06KYMRKymera TherapeuticsN/A10.8110.81QUREuniQure0.3310.4010.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTKCytokineticsN/AKRYSKrystal Biotech86.29%KYMRKymera TherapeuticsN/AQUREuniQure78.83%Insider OwnershipCompanyInsider OwnershipCYTKCytokinetics2.60%KRYSKrystal Biotech13.10%KYMRKymera Therapeutics15.98%QUREuniQure4.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYTKCytokinetics250124.43 million121.20 millionOptionableKRYSKrystal Biotech21029.48 million25.62 millionOptionableKYMRKymera Therapeutics17082.26 million69.11 millionOptionableQUREuniQure50063.07 million60.13 millionOptionableQURE, KRYS, CYTK, and KYMR HeadlinesRecent News About These CompaniesuniQure N.V. (NASDAQ:QURE) Given Consensus Recommendation of "Moderate Buy" by AnalystsJuly 13 at 2:14 AM | americanbankingnews.comuniQure N.V. (NASDAQ:QURE) Receives Average Rating of "Moderate Buy" from BrokeragesJuly 13 at 2:13 AM | marketbeat.comuniQure N.V. $QURE Shares Purchased by Y Intercept Hong Kong LtdJuly 10 at 6:31 AM | marketbeat.comMatthew Kapusta Sells 21,082 Shares of uniQure (NASDAQ:QURE) StockJuly 8, 2026 | insidertrades.comuniQure, Protara, Abeona, Cerebras, Verisign Insider Shake-UpJuly 4, 2026 | tipranks.comInsider Selling: uniQure (NASDAQ:QURE) Director Sells $982,995.48 in StockJuly 3, 2026 | insidertrades.comuniQure (NASDAQ:QURE) Director Jack Kaye Sells 21,167 SharesJuly 2, 2026 | marketbeat.comWalid Abi-Saab Sells 30,000 Shares of uniQure (NASDAQ:QURE) StockJuly 2, 2026 | marketbeat.comWhich Is a Better Investment, uniQure N.V. or Viridian Therapeutics, Inc. Stock?July 2, 2026 | aaii.comA16 Stocks That Could Squeeze Shorts This MonthJuly 2, 2026 | schaeffersresearch.comuniQure (QURE) Now Trades Above Golden Cross: Time to Buy?July 1, 2026 | zacks.comHC Wainwright Has Bullish Forecast for uniQure Q2 EarningsJuly 1, 2026 | marketbeat.comWalid Abi-Saab Sells 1,434 Shares of uniQure (NASDAQ:QURE) StockJuly 1, 2026 | insidertrades.comAssenagon Asset Management S.A. Decreases Stake in uniQure N.V. $QUREJuly 1, 2026 | marketbeat.comuniQure (NASDAQ:QURE) Stock Price Expected to Rise, HC Wainwright Analyst SaysJune 29, 2026 | marketbeat.comInsider Selling: uniQure (NASDAQ:QURE) CEO Sells 6,696 Shares of StockJune 27, 2026 | insidertrades.comSG Americas Securities LLC Increases Stock Position in uniQure N.V. $QUREJune 27, 2026 | marketbeat.comuniQure Closes $259 Million Public Offering of Ordinary SharesJune 25, 2026 | quiverquant.comQuniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional SharesJune 25, 2026 | globenewswire.comUniQure N.V. (QURE) Upgraded to Overweight as Huntington’s Disease Program AdvancesJune 25, 2026 | finance.yahoo.comuniQure Completes Upsized Public Equity Offering for GrowthJune 24, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026The Oil Trade May Not Be Over: 3 Energy Stocks to WatchBy Thomas Hughes | June 21, 20263 Biotech Firms With Major Potential Catalysts in the Coming MonthsBy Nathan Reiff | June 21, 2026QURE, KRYS, CYTK, and KYMR Company DescriptionsCytokinetics NASDAQ:CYTK$84.87 0.00 (0.00%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$84.90 +0.03 (+0.04%) As of 08:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Krystal Biotech NASDAQ:KRYS$365.81 0.00 (0.00%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$370.40 +4.59 (+1.25%) As of 08:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Kymera Therapeutics NASDAQ:KYMR$119.35 0.00 (0.00%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$115.96 -3.39 (-2.84%) As of 08:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.uniQure NASDAQ:QURE$42.63 0.00 (0.00%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$42.57 -0.06 (-0.14%) As of 08:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/06 - 07/10 Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing Why WD-40 Is Proving Great Businesses Never Go Out of Style Rocket Lab’s Stock Drop Comes With a Bullish Twist Why "Big Short" Investor Michael Burry Sees Upside in Beaten-Down Sportbook Stocks Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs Power Struggle: Wolfspeed Sues Navitas Over AI Chips Pushing the Edge: Super Micro Computer Reboots the AI Landscape Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
